A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies (Q33342817)

26 July 2017

title

A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies (English)

1 reference

adaptive radiation therapy

26 July 2017

main subject

0 references

1 reference

U N Vaishampayan

1

1 reference

26 July 2017

E Ben-Josef

2

1 reference

26 July 2017

P A Philip

3

1 reference

26 July 2017

V K Vaitkevicius

4

1 reference

26 July 2017

W Du

5

1 reference

26 July 2017

K J Levin

6

1 reference

26 July 2017

A F Shields

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

International Journal of Radiation Oncology Biology Physics

26 July 2017

published in

1 reference

26 July 2017

volume

53

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

675-679

1 reference

Irradiation Plus 5-Fluorouracil: Cellular Mechanisms of Action and Treatment Schedules

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Potential of Xeloda in colorectal cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902772-4

7 January 2021

10.1016/S0360-3016(02)02772-4

Identifiers

DOI

1 reference

26 July 2017

1 reference